Performance in Initiating Clinical Research - Quarter 2 (2019/20)

Note: Chelsea and Westminster Hospital NHS Foundation Trust formally acquired West Middlesex University Hospital NHS Foundation Trust on 01 September 2015 and the submission for the former West Middlesex University Hospital NHS Foundation Trust has been subsumed into

All clinical

al	trials	hosted	between	1st Octobe	r 2018	and	30th	Septemb	er 2019	7
HRA Approval studies										

Id	Research	Integrated	Name of Trial	Date Site	Date Site	HRA Appi	roval studies Date Site	Date Site	Date Site	Date of First	Comments	Reasons for Delay correspond to
	Ethics Committee	Research Application		Invited	Selected	Approval Date	Confirmed By Sponsor	Confirmed	Ready To Start	Participant Recruited		
	Reference Number	System Number										
	18/WA/0161	238902	An open-label, multi-centre, randomised, switch study to evaluate the virological efficacy over 96	10/09/2018	08/11/2018	04/10/2018	07/12/2018	18/12/2018	19/12/2018	12/03/2019	Site had a pool of potentially eligible patients whose medication was changed	NHS Provider
			weeks of 2-drug therapy with DTG+RPV FDC in antiretroviral treatment-experienced HIV-1 infected								during set up resulting in them no longer being eligible.	
			subjects virologically suppressed with NNRTIs resistance mutation K103N (WISARD)									
454224	40/514/0020	220452	The International I	24/00/2040	22/44/2040	05/43/3040	20/44/2040	05/42/2040	07/47/2040	04/04/2040	None	
	18/SW/0039	229163	The 'Big Baby Trial'	24/09/2018	23/11/2018	05/12/2018	28/11/2018	05/12/2018	07/12/2018	04/01/2019	None	
151325	18/LO/2068	254238	A multicenter, open-label, sponsor-blinded, randomized, active-controlled, parallel group,	19/09/2018	12/11/2018						REC unfavourable opinion. Sponsor resubmitting to REC and HRA. No HRA	Sponsor
			pivotal study to evaluate the efficacy, safety, and tolerability of murepavadin given with ertapenem								Approval in place yet.	
			versus an anti-pseudomonal ?-lactam-based antibiotic in adult subjects with nosocomial									
			pneumonia suspected or confirmed to be due to Pseudomonas aeruginosa.									
	17/LO/2093	228763	A phase IV, open-label pilot study investigating non- invasive markers of hepatic fibrosis in people living	11/06/2018	14/02/2019	26/02/2018	18/02/2019	19/02/2019	20/02/2019	13/05/2019	None	
			with HIV-1 and non-alcoholic fatty liver disease randomised to receiving optimised background									
			therapy (OBT) plus maraviroc or OBT									
151327	16/WS/0057	193580	A randomised, open-label trial of a Multimodal	14/11/2018	07/02/2019	04/08/2016	12/04/2019	18/03/2019	12/04/2019	30/09/2019	Study difficult to recruit - rare patients	Neither
			Intervention (Exercise, Nutrition and Anti- inflammatory Medication) plus standard care versus									
			standard care alone to prevent / attenuate cachexia in advanced cancer patients undergoing									
			chemotherapy.									
151328	18/SC/0454	249509	Perioperative Ischemic Evaluation-3 Trial	05/02/2019	05/02/2019	16/01/2019	18/03/2019	22/03/2019	19/08/2019	17/09/2019	SIV delayed. Sponsor green light issued 19/08/19. Site had to recruit new staff to	Both
											work on study.	
	18/YH/0017	231431	Improving the safety and continuity of medicines management at care transitions	23/08/2018	11/01/2019	01/03/2018	11/01/2019	19/02/2019	03/04/2019	15/04/2019	None	Please Select
151330	18/LO/1537	227239	A single centre randomised controlled trial	23/04/2018	18/01/2019	18/01/2019	08/05/2019	08/05/2019	09/05/2019	10/05/2019	Research team amended protocol and	Sponsor
			investigating the efficacy of The Zoo, a form of digital distraction as an analgesic and anxiolytic in								CRF prior to green light causing delay in recruitment	
			the paediatric emergency department									
454224	40/10/2022	252204	Who had a laborate to the same and the same	42/02/2040	04/04/2040	40/04/2040	07/05/2040	07/05/2040	05/05/2040	00/00/2040	A. C. Waller and A. C. Waller and D. Waller	NUC Book to
	18/LO/2033	252294	When to Induce Labour to Limit risk in pregnancy hypertension ? a multicentre, randomised	13/02/2019	04/04/2019	10/01/2019	07/05/2019	07/05/2019	06/06/2019	08/08/2019	An initial cohort of potentially eligible patients was identified but following	NHS Provider
			controlled trial								green light none were eligible due to developing pre-eclampsia	
						/ /						
	18/LO/1352	243519	A Phase 3 Randomized, Placebo-Controlled, Double- Blind Study to Evaluate Upadacitinib in Adolescent	07/09/2018	09/04/2019	03/01/2019	17/04/2019	17/04/2019	23/04/2019	05/06/2019	None	
			and Adult Subjects with Moderate to Severe Atopic Dermatitis									
151333	16/LO/1318	187932	Nucleos(t)ide withdrawal in HBeAg negative	25/10/2018	12/04/2019	21/09/2016	07/05/2019	08/05/2019	14/05/2019		None	
			hepatitis B virus infection to promote HBsAg clearance. (NUC-B)									
	19/SC/0122	259342	A Randomized, Double-Blind, Placebo-Controlled Study of Diazoxide Choline Controlled-Release	25/10/2018	08/05/2019	07/05/2019	23/05/2019	23/05/2019	04/06/2019	10/07/2019	None	
			Tablet (DCCR) in Patients with Prader-Willi Syndrome									
151335	19/LO/0400	250289	The Impact of using FilmArray Pneumonia Panel Molecular Diagnostics for Hospital-Acquired and	01/04/2019	02/06/2019	09/04/2019	01/07/2019	02/07/2019	04/07/2019	30/07/2019	None	
			Ventilator-Associated Pneumonia on Antimicrobial Stewardship and Patient Outcomes in UK Critical									
			Care: A Multicentre Randomised Controlled Trial.									
151336	17/LO/0621	191390	STandard versus Accelerated initiation of Renal Replacement Therapy in Acute Kidney Injury	16/11/2018	03/06/2019	22/05/2017	18/06/2019	19/06/2019	05/07/2019		None	
			(STARRT-AKI): A Multi-Centre Randomized Controlled Trial									
151337	19/LO/0666	261913	Pharmacokinetics of plasma doravirine once daily	01/01/2019	10/06/2019	10/06/2019	10/06/2019	10/06/2019	12/06/2019	25/06/2019	None	
			over 72 hours following drug intake cessation in healthy volunteers									
151338	18/WM/0352	241385	An Open-Label, Multi-Centre, Randomised Study to Investigate Integrase Inhibitor Versus Boosted	21/01/2019	21/03/2019	15/01/2019	08/04/2019	18/04/2019	09/05/2019	21/06/2019	Site target just 2 patients - study very difficult to recruit to.	Both
			Protease Inhibitor Antiretroviral Therapy for Patients with Advanced HIV Disease. The Late									
			Presenter Treatment Optimisation Study (LAPTOP).									
153030	19/LO/0905	257865									None	
153031	19/EE/0185	260536	PIBIK Study	02/05/2019	05/08/2019	17/07/2019	21/08/2019	10/09/2019	25/09/2019	16/09/2019	None	
			FIRST-line support for Assistance in Breathing in Children (FIRST-ABC)	04/06/2019	07/08/2019	26/07/2019	04/09/2019	06/09/2019	09/09/2019			
153032	19/NS/0162	264547				20/07/2019	04/U9/2U19	00/09/2019	02/02/2019		None	
153033	19/LO/0040	253233	SMOKEFREE	28/08/2019	28/08/2019						None	
15255	10/10/20:-		Apremilast Phase4 Study on Quality of life in psoriasis manifestations	27/03/2019	29/08/2019	19/02/2019	12/09/2019	17/09/2019	18/09/2019		None	
153034	19/LO/1043	261870	Ertugliflozin versus Placebo in Paediatric Type 2								None	
153035	17/EE/0347	201505	Diabetes	19/06/2019	07/09/2019	07/10/2019	26/09/2019	02/10/2019			None	
			IASO	12/09/2019	12/09/2019	17/10/2017	11/10/2019	15/10/2019				
153036	18/EM/0310	239782		12/03/2019	12/09/2019	1//10/201/	11/10/2019	15/10/2019			None	
			C-STICH2 Randomised controlled trial of emergency cerclage	09/05/2019	12/09/2019	16/11/2018						
	19/LO/0452	250324	CASTLE TRIAL v1.0	29/07/2019	13/09/2019	02/05/2019	01/10/2019	25/09/2019			None	
153038	19/WA/0005	246081							21/10/201		None	
			IP2 - ATLANTA	1//09/2019	24/09/2019	14/03/2019	21/10/2019	1//10/2019	21/10/2019			